Carfilzomib based treatment strategies in the management of relapsed/refractory multiple myeloma with extramedullary disease
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: Cancers (2020) 12:4, 1035. https://doi.org/10.3390/cancers12041035
- Ereignis
-
Veröffentlichung
- (wo)
-
Würzburg
- (wer)
-
Universität Würzburg
- (wann)
-
2022
- Urheber
-
Zhou, Xiang
Flüchter, Patricia
Nickel, Katharina
Meckel, Katharina
Messerschmidt, Janin
Böckle, David
Knorz, Sebastian
Steinhardt, Maximilian Johannes
Krummenast, Franziska
Danhof, Sophia
Einsele, Hermann
Kortüm, Martin
Rasche, Leo
- DOI
-
10.3390/cancers12041035
- URN
-
urn:nbn:de:bvb:20-opus-203704
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:31 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Zhou, Xiang
- Flüchter, Patricia
- Nickel, Katharina
- Meckel, Katharina
- Messerschmidt, Janin
- Böckle, David
- Knorz, Sebastian
- Steinhardt, Maximilian Johannes
- Krummenast, Franziska
- Danhof, Sophia
- Einsele, Hermann
- Kortüm, Martin
- Rasche, Leo
- Universität Würzburg
Entstanden
- 2022
Ähnliche Objekte (12)
Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma
Salvage therapy with "Dara-KDT-P(A)CE" in heavily pretreated, high-risk, proliferative, relapsed/refractory multiple myeloma
Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies
Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma
Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma
Ärztlich assistierte Selbsttötung - Umgang mit Anfragen von Krebspatientinnen und Krebspatienten : Beiträge zur Gestaltung einer herausfordernden Praxis
Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns
Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns
Superlubricitive engineering—Future industry nearly getting rid of wear and frictional energy consumption
VIPER: variability-preserving imputation for accurate gene expression recovery in single-cell RNA sequencing studies
SRT-Server: powering the analysis of spatial transcriptomic data
N4 DNA recognition by STAT6: structural and functional implications
Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma
Salvage therapy with "Dara-KDT-P(A)CE" in heavily pretreated, high-risk, proliferative, relapsed/refractory multiple myeloma
Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies
Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma
Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma
Ärztlich assistierte Selbsttötung - Umgang mit Anfragen von Krebspatientinnen und Krebspatienten : Beiträge zur Gestaltung einer herausfordernden Praxis
Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns
Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns
Superlubricitive engineering—Future industry nearly getting rid of wear and frictional energy consumption
VIPER: variability-preserving imputation for accurate gene expression recovery in single-cell RNA sequencing studies
SRT-Server: powering the analysis of spatial transcriptomic data
N4 DNA recognition by STAT6: structural and functional implications
Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma
Salvage therapy with "Dara-KDT-P(A)CE" in heavily pretreated, high-risk, proliferative, relapsed/refractory multiple myeloma
Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies
Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma
Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma
Ärztlich assistierte Selbsttötung - Umgang mit Anfragen von Krebspatientinnen und Krebspatienten : Beiträge zur Gestaltung einer herausfordernden Praxis
Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns
Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns
Superlubricitive engineering—Future industry nearly getting rid of wear and frictional energy consumption
VIPER: variability-preserving imputation for accurate gene expression recovery in single-cell RNA sequencing studies
SRT-Server: powering the analysis of spatial transcriptomic data